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Objective. To determine feasibility and preliminary effects of an occupational therapy treatment 
to improve upper extremity (UE) function in patients with early systemic sclerosis (SSc) who 
have UE contractures. 
Methods. A one-arm pilot clinical rehabilitation trial was conducted at a university health 
system. Participants with SSc and > 1 UE contracture (n = 21) participated in a total of 8 weekly 
in-person occupational therapy sessions. The therapy consisted of thermal modalities, tissue 
mobilization, and UE mobility. Between sessions, participants were instructed to complete UE 
home exercises. Feasibility was measured by percent enrollment and session attendance and 
duration. The primary outcome measure was the QuickDASH, secondary and exploratory 
outcomes included PROMIS physical function, objective UE measures, and skin thickening. 
Linear mixed models were performed to determine treatment effects on primary and secondary 
outcomes.  
Results. Fifty percent (24/48) of potentially eligible participants were interested. Of those, 88% 
(21/24) enrolled; and nineteen out of 21 (91%) completed all sessions. The mean (SD) age was 
47.9 years (+ 16.1); 100% had diffuse SSc, and mean disease duration was 3.1 years. At 8 
weeks, participants reported statistically significant improvement on QuickDASH and PROMIS 
physical function measures (p =.0012 and p = .004). Forty-seven and 53% percent of the 
sample achieved improvements that exceeded minimally important differences.  
Conclusion. In-person treatment sessions were feasible for individuals with SSc and 
demonstrated statistically significant and clinically meaningful improvements on UE and physical 
function. Future studies need to examine effects against a control condition and examine 
durability of treatment effects.   
 
Significance and Innovations 
• In a pilot test of occupational therapy treatment consisting of thermal modalities, tissue 
mobilization, range of motion exercises, functional activities and home exercises,  
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improvements in reported UE and physical function and some objective performance 
measures were found in a small cohort of individuals with early systemic sclerosis.  • Eight weekly occupational therapy sessions plus home exercises was highly feasible for 
participants despite burden of travel to the clinic. • The standardized therapy manual created in this study has the potential to be 
disseminated to the occupational therapy community after further testing in larger 
studies which could increase clinical uptake of an evidence-based intervention for early 
systemic sclerosis.   
 
 
  
 
Systemic sclerosis (SSc) is a rare, debilitating disease of the connective tissue that not only 
affects the skin, but also can cause severe damage to the internal organs. Despite gains in drug 
therapies to help control symptoms, patients with SSc face a significant challenge of managing 
a chronic disease that has a huge impact on daily life. Musculoskeletal complications of SSc 
can be severe, especially in early disease (1, 2). In particular, skin thickening and joint 
contractures in the upper extremities limit the ability to perform daily activities and are 
associated with disability (3, 4) and reduced quality of life (5-7).  
 
Evidence-based, rehabilitation interventions for the upper extremity (UE) in SSc are limited. 
Treatments that have some evidence supporting effects include thermal modalities such as 
paraffin wax baths (10-12); range of motion exercises (13, 14); and manual therapies including 
tissue mobilization and lymphatic drainage (15-17). Moreover, there are few high quality clinical 
trials (8, 9). Most studies are not randomized, have small samples, use many different outcome 
measures, and have various forms of treatments, treatment delivery, and dose which limits 
comparison (8, 9). To date, there has only been one large multi-site randomized controlled trial 
testing a rehabilitation intervention for SSc in which 220 participants were randomized either to 
an individualized 4-week physical and occupational therapy intervention or usual care (18). This 
study demonstrated that intensive rehabilitation treatment for SSc involving exercise not 
exclusive to the UE had, at minimum, short-term benefits on reported disability and some 
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objective mobility measures. However, the intervention did not include evidence-based 
treatments such as thermal modalities or tissue mobilization, and a large portion of intervention 
was devoted to splinting, which has little evidence to support its use in SSc (9, 19, 20).  
 
To address the shortcomings of the knowledge base on UE interventions in SSc, our study team 
was interested in testing an intervention that comprised evidence-based components and that 
could eventually be easily disseminated in practice. The majority of occupational therapists who 
come into contact with an SSc patient may have little to no experience treating this disease due 
to the rarity of the disease. Thus, part of this study was devoted to developing and testing a 
standardized treatment manual that included instruction for therapists regarding adaptations for 
patients with different UE problems that would facilitate translation into practice once the 
intervention is fully evaluated and support for effectiveness can be established.  
 
The purpose of this pilot study was to test the feasibility and preliminary effects of a standard 
provision of an in-person 8-week occupational therapy treatment with prescribed home 
exercises to improve UE function in individuals with early SSC who had contractures. The 
intervention believed to be most effective for SSc patients by our team involved a minimum of 8 
in-person visits with the occupational therapist. Because of the rarity of SSc and the fact that 
many SSc patients travel to the health system from long distances, it was necessary to examine 
feasibility of this intervention. In addition to feasibility, we examined the preliminary effects of 
treatment over time using the QuickDASH measure of UE function, the PROMIS measure of 
physical function; objective measures of UE mobility, strength, and coordination; and skin 
thickening. We hypothesized that the treatment would be feasible to deliver and that it would 
demonstrate preliminary effects on patient-reported functional measures.   
 
PARTICIPANTS AND METHODS 
Design. This pilot study used a one-group pretest posttest design with a target sample of 20 
individuals with SSc. Outcome measures were collected at baseline, at 4 weeks (mid-treatment) 
and at 8 weeks (immediately following treatment).   
 
Sample. Participants were recruited from the Scleroderma Center at the University of Michigan 
Health System from September 2016 – May 2017. Potential participants were either contacted 
from an established research registry at the Scleroderma Center or were contacted at their clinic 
visit if they appeared to meet the inclusion criteria based on review of their electronic medical 
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records. To be eligible for this study, participants needed to be 18 years of age or older; have 
SSc; have a contracture of the hand and another joint in at least one arm such as wrist or elbow 
with ability to demonstrate active range of motion in that arm; English speaking; have no active 
hand ulcers; no concurrent medical issues; and willingness to travel to the Scleroderma Center 
for treatments. We focused on patients with early SSc with diffuse cutaneous distribution as our 
hypothesis was that early UE contractures are related to active and progressive skin and joint 
disease and are amenable to treatment, whereas late disease reflected greater damage and 
does not improve with therapy. We considered early SSc to be less than 5 years after onset 
similar to a previous study (21).  
 
Procedure. The research coordinator met with potential participants who were initially eligible 
based on a phone screening or review of their electronic medical records prior to a clinic visit. 
After eligibility was confirmed and informed consent was obtained, participants were scheduled 
for a baseline visit with the occupational therapist. The therapist administered questionnaires to 
evaluate UE function (QuickDASH) and overall physical function (PROMIS), and she conducted 
active and passive range of motion assessments, skin assessments, grip/pinch strength and 
administered tests of hand coordination. These outcome assessments occurred at baseline, at 4 
weeks, and at 8 weeks. Treatment was conducted each week over 8 weeks at the outpatient 
rehabilitation clinic in the university health system. It involved preparatory thermal modalities, 
tissue mobilization, and UE mobility beginning with passive range of motion and ending with 
active range of motion (shown in Table 1). Tissue mobilization was done using the Physiotouch 
device, also called the Lymphatouch [Healthy Life Devices Ltd, Helsinki, Finland]. The 
Physiotouch is a negative pressure device that has been used primarily to decrease swelling in 
tissue (22), but is currently being used in our health system as a treatment for SSc patients 
because it delivers mild tissue mobilization (23) which may provide better mobilization than 
manual techniques. The therapist also instructed participants on a home range of motion 
exercise program that was tailored as needed to each participant based on the severity of their 
contractures and arm mobility. Participants were instructed to complete daily exercise sessions 
at home.      
 
Development of standardized treatment manual. The treating therapist, therapist consultant (a 
certified hand therapist with over 30 years of experience treating individuals with scleroderma), 
and principal investigator developed an initial guide for treatment reflected in Table 1. The 
treatment components were chosen based on support of their effects in the literature (thermal 
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modalities, tissue mobilization, and range of motion) and reflected current practices within our 
clinic. During each treatment session, the therapist logged the duration of each treatment 
component and noted any adaptations made to treatment based on an individual's disease 
severity or specific impairments. After all participants completed treatment, the treatment 
manual was reviewed and detail was included to provide instruction on how to deliver the 
intervention. An excerpt of the treatment manual is provided in the Appendix.  
 
Feasibility measures. We tested feasibility against a-priori criteria: 1) At least 50% of participants 
who were eligible for the study would enroll; 2) At least 80% of participants would attend all 
treatment sessions; and 3) The sessions that included both treatment and outcome 
assessments would not last on average more than 2 hours. We assessed how many people 
initially approached, either through call or in-person at their clinic visit, and were interested in 
participating in the treatment. We also assessed what percentage of participants completed all 8 
sessions. We examined the feasibility of providing treatment that can potentially be provided via 
outpatient visits. Thus, we assessed the length of time needed to complete all procedures in the 
in-person sessions.   
 
Primary outcome. The primary outcome was UE function as measured by the shortened 
Disability Arm Shoulder Hand questionnaire called the QuickDASH, a reliable and validated self-
reported measure used in the SSc population (24, 25). This is an 11-item questionnaire in which 
difficulty in several tasks involving the upper extremity are rated as well as interference and 
severity of symptoms. Items are averaged and converted to a 0 – 100 scale; a higher score 
indicates worse function. This measure is responsive to change and the minimal clinically 
important difference in patients with shoulder and arm limitations is a 16 point decrease (26). 
 
Secondary outcomes. The secondary outcomes included general reported physical function as 
assessed by the PROMIS physical function version 2.0 8 item short form; the US population 
mean score is 50 with SD of 10, and a higher score denotes better function (27). A 2-point 
improvement in T-score is considered a clinically meaningful improvement (28). The main 
measure of range of motion was total active hand motion for the right and left hands. This was 
calculated by summing the total active range of motion for each finger and thumb by goniometer 
(260 degrees in each finger and 135 in the thumb) (29); a total score of 1125 was possible for 
each hand. The therapist also took photos of participants demonstrating each range of motion in 
the UEs at each outcome assessments as another way to examine change over time. 
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Coordination was measured by the 9 hole peg test, a commonly-used test of dexterity in which 
an individual needs to put 9 pegs in holes on a peg board while timed (30). Handgrip strength 
was measured in pounds of pressure by Jamar hand dynamometer [Lafayette Instruments, 
Lafayette IL] according to a standardized protocol in which the participant squeezes the 
dynamometer while seated with their elbow at a 90 degree angle (31). The value used was the 
maximum of 6 trials, 3 trials for each UE.  
 
Exploratory outcomes. Outcomes considered exploratory were measures considered by 
therapist team to be important in UE function but may not have been as directly impacted by the 
treatment. These outcomes included: 1) active range of motion of wrist flexion and elbow flexion 
for each UE measured by goniometer; 2) lateral pinch strength, measured by pinch gauge in 
which an average of 3 trials was used (31); and 3) skin thickness assessed by the modified 
Rodnan skin score (32). The modified Rodnan score was assessed at baseline and at 8 weeks 
by a clinic rheumatologist who was not part of the study team.  
 
Sample size determination. Twenty participants was the target sample size, which was thought 
to be sufficient to establish feasibility over the one year period of the study. With 20 participants, 
we determined that at 80% power we could detect an effect of .67 standard deviation units, 
which is about a 16 point change on the QuickDASH measure, a cut-off reported for the 
minimally clinically important difference in patients with shoulder limitations (25).  
 
Statistical Analysis. We used descriptive statistics to examine feasibility of study processes 
and treatment protocol and compared them to our a-priori criteria for success. To examine the 
change over time from baseline, 4- and 8-week assessments in our primary and secondary 
outcome measures, we used linear mixed models using all available data which served as an 
intent-to-treat analysis. For exploratory outcomes, we performed a per-protocol analysis in 
which completer data was examined for change over time using one way repeated measures 
analyses of variance or paired t-tests.  
  
RESULTS 
Participant flow and characteristics. Figure 1 shows the participant flow through the study. 
There were 48 potentially eligible participants from the chart review and early scleroderma 
research registry who were either approached at a clinic visit or by phone (if on the registry) and 
of these, 24 (50%) were interested and consented. A main reason for not participating was 
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travel burden. Individuals who were interested were screened in person and completed the 
informed consent process. One person did not meet the study eligibility criteria, and two people 
did not choose to participate due to not being able to get time off of work or being unable to 
schedule for visits. Twenty one participants were enrolled in the treatment and two were lost to 
follow-up due to travel constraints; despite their interest in participating, round trip mileage to the 
Center for treatment ranged between 200 – 550 miles per session.  
 
Baseline characteristics of the sample (N = 21) are shown in Table 2. Participants were 
predominantly female and 38% identified as a racial minority, with almost one quarter of the 
sample identifying as African American. Participants ranged in age from 20 – 75 years, with a 
mean of 47.9 years. All participants had diffuse cutaneous SSc. The mean duration of SSc was 
3.1 + 2.3 years; with a mean (SD) Rodnan score of 17.6 (9.7) indicating moderate skin disease. 
Majority of patients were being treated with immunosuppressive therapy or were in ongoing 
clinical trials for their aggressive skin disease. 
 
Feasibility outcomes. Nineteen participants (91% of the enrolled sample) completed the 
protocol as intended, attending all 8 in-person sessions. These participants traveled a mean of 
103.4 + 82.5 miles round trip for each session with 37% traveling between 100 and 
approximately 340 miles each session. There were a few protocol deviations due to timing of 
sessions. One participant stopped and restarted treatment two months later due to travel issues, 
but then was able to attend all 8 sessions. Fifteen of the 19 participants who attended all 
sessions attended them weekly; whereas the remaining four had at least one cancellation and 
rescheduled for the next available slot (usually the following week). There was also a protocol 
deviation due to a participant being treated with an active hand ulcer and one person having a 
fingernail fall off during the course of treatment, which are relatively common phenomenon in 
SSc. Both participants received modified treatment modalities (such as no paraffin treatment to 
affected hands) in these cases. We also evaluated the time it took to administer sessions in 
which evaluation plus treatment sessions were combined (at baseline, 4 weeks, and 8 weeks) 
for feasibility of administration. Ten percent of evaluation plus treatment sessions (6/59 total 
sessions) lasted longer than 2 hours, which exceeded our feasibility target; however, five of 
those sessions occurred at baseline and the therapist was able to improve process efficiency at 
almost all the subsequent sessions.   
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Adverse events and unanticipated problems. With regard to adverse events and 
unanticipated problems, there were no related adverse events or unanticipated problems of 
treatment. One participant experienced a fingernail falling off prior to returning for the last 
session of treatment and was considered unrelated to the treatment provided. For the last 
session of treatment, any treatment or outcome measures concerning that digit were not 
performed.   
 
Effects of treatment. Table 3 shows the results of the each outcome using linear mixed 
models. Participants had a mean of 6.6 point improvement on the QuickDASH at 4 weeks which 
was not significant; however, participants continued to improve from 4 to 8 weeks with a 14 
point mean improvement from baseline [t (2,36) = 3.53; p =.0012]. Using a previously cited 
clinically meaningful cut-point of 16 point improvement on the QuickDASH (25); 47% of 
participants who completed the intervention (9/19) met this threshold.    
 
On the PROMIS physical function measure, participants had a significant improvement over the 
8 week period from baseline. Similar to the QuickDASH trends, change from baseline to 4 
weeks was not significant; however, improvements continued from 4 to 8 weeks and was a 
significant effect [t(2,36) = -3.08; p = .004]. The mean improvement over time was 3.1 points on 
the PROMIS which demonstrates a third of a standard deviation change; larger than the 
minimally important difference of 2 points on the PROMIS 20-item physical function scale in a 
rheumatoid arthritis sample (28). Fifty three percent achieved a 2-point increase on the PROMIS 
after 8 weeks.   
 
Of the objective UE measures, left total active hand function and left 9 hole peg test scores 
were significantly improved after the intervention. On average, participants gained 41.5 degrees 
of active hand motion at 8 weeks and were 2.5 seconds faster at performing the 9 hole peg test 
with their left hands. There are no established clinically important differences in either of these 
measures. Figure 2 shows examples of improvement from baseline to 8 weeks in active range 
of motion. No significant improvement was shown on active hand motion or coordination for the 
right hand after 8 weeks. Handgrip strength did not improve, and participants had a slightly 
weaker handgrip at 8 weeks, although findings were not statistically significant (p = .06). For the 
exploratory outcomes, there were no statistically significant changes in wrist or elbow flexion or 
lateral pinch measures. Skin thickness, evaluated by modified Rodnan score was captured on 
15 participants at post-test, and a paired t-test on completer data showed no significant change 
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and slight worsening from baseline to 8 weeks [17.9 (+7.9) baseline, 20.1 (+9.5) 8 weeks; t 
(1,14) = -1.4; p = .18].    
 
DISCUSSION 
In this study, we examined the feasibility and preliminary effects of an 8 session in-person 
occupational therapy treatment to improve UE outcomes in individuals with SSc. In general, the 
study and the treatment were feasible supported by our ability to enroll and retain participants 
despite the travel burden to the center. Of 47 eligible participants, 48 potentially eligible 
individuals minus one who did not meet the inclusion criteria for contracture type, 51% were 
enrolled in the treatment, which was slightly above our target of 50%. Attendance at all 8 
sessions for those enrolled exceeded our expectations in that 91% of the sample met this metric 
despite the burden of traveling a mean distance of over 100 miles roundtrip for each session. In 
an attempt to reduce participant travel burden, we consolidated treatment and outcome visits at 
baseline, 4 weeks, and 8 weeks. We examined feasibility of conducting these combined 
sessions in a 2 hour period and 90% of sessions met this criterion. The sessions that exceeded 
the time limit occurred early in the study and timing improved as the therapist was able to 
streamline processes. The treatment provided showed the strongest effects on reported 
improvement in UE function and general physical function and improvements were considered 
clinically important for approximately half of the sample on the QuickDASH and PROMIS 
physical function measures (47% and 53% respectively) per established cut-offs in other 
populations (26, 28). Without studies in SSc evaluating these clinically important differences, it 
is not clear whether this is an accurate reflection of who benefited as a result of this treatment. 
For instance, depending upon the study, different values of minimal clinically important 
differences for QuickDASH have been reported; one study reported a cut-off score of 8 and 
another reported 14 (24, 33). Thus, our chosen cut-off of 16 points is likely conservative, and 
more individuals in our sample may have benefitted. 
  
Improvements were shown in some but not all objective measures, and most improvement 
occurred in hand mobility and coordination. Significant effects were shown only in the left hand, 
although both hands had similar trends of improvement. Interestingly, more gains occurred in 
the first 4 weeks of treatment. However, gains in these measures continued from 4 – 8 weeks 
showing that the additional sessions were valuable. It remains unclear how many sessions are 
optimal for sustaining gains made during treatment. Most studies investigating UE rehabilitation 
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interventions in SSc were designed to measure short-term efficacy with end-points spanning 
from 4 weeks to 3 months (11, 12, 14-17) and most clinic-based interventions lasted from 3 – 8 
weeks, however intensity of these interventions was variable. The highest quality randomized 
controlled trial in this evidence base from Rannou and colleagues showed a 3-week intensive 
intervention, consisting of 36 treatment hours and a prescribed daily home exercise program, 
had short term effects on disability on the Health Assessment Questionnaire that diminished 
over time at 6 months and 12 months follow-up (18). Although long-term adherence to the home 
exercise program was poor, participants who adhered to the daily home exercises had better 
effects than those that did not over time, supporting the inclusion of home exercise in future 
interventions. Home exercise programs likely need to be more engaging to participants to 
improve adherence in future studies.   
      
A main strength of this study includes testing a treatment informed by available evidence 
supporting specific treatment components in SSc that capitalized on the extensive experience of 
our therapist team who commonly provide UE treatment for individuals with SSc. In addition, the 
creation of a standardized manual as done in this study (see Appendix for an excerpt) will be 
important for further testing of this intervention and has the potential to provide an evidence-
based guide for therapists who treat patients with SSc on a broad scale.  
This study is limited by conclusions that can be drawn due to its one group design. Thus, the 
assessment of outcomes in this study does not provide definitive evidence of efficacy of 
treatment. Further, due to the size and scope of this study, the therapist also served as the 
outcome assessor and therefore was not blinded. Tracking of home exercise needs to be 
strengthened in future studies as we did not formally assess adherence. Thus, it was not 
possible to disentangle the effects of home exercise from that of in-person sessions. 
Understanding the effects of in-person intervention versus home exercise will be important in 
future research studies since participation in the intervention was mainly precluded by travel to 
the center. Given that our sample included all participants with diffuse SSc who were in the 
early stages of the disease (within 5 years of diagnosis), our findings can only be generalized to 
this population. In addition, we are uncertain if these improvements are maintained after the in-
person sessions were completed in the trial.  
 
In conclusion, this pilot one group trial supported the feasibility of an 8 session occupational 
therapy intervention to address UE function in individuals with SSc. Preliminary effects were 
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found at 8 weeks with reported improvements in UE disability, physical function, and objective 
measures of hand mobility and coordination. Although definitive treatment effects cannot be 
drawn from this study, therapists unfamiliar with treating SSc may benefit from reviewing 
information on the treatment provided to gain knowledge of progression of treatment 
components and recommended adaptations based on individual differences. Further larger 
studies are needed that include a control group or comparator arm and examine durability of 
treatment effects.   
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Table 1. Treatment Protocol 
 
Table 2. Baseline Characteristics of Sample N = 21 
Characteristics  
Age, (mean, SD) 47.9 (16.1) range 20 - 75 
Female (%, n) 86%, 18 
Race (%, n) 38.1%, 8  
   Black/African American 23.8% 5 
   White 61.9% 13 
   Other 14.3% 7 
Ethnicity (%, n) 4.8% 1 
   Hispanic or Latino 61.9% 13 
   Other 33.3% 7 
Married (%, n) 47.6%, 10 
High school education or less (%, n) 38.1%, 8 
Modified Rodnan Skin Score, (mean, SD)*  17.6 (9.7) range 1 – 37 
Focus Area Technique 
Preparation for Treatment Thermal Modalities  Hot packs –  focused on areas with limitations  Paraffin – focused on digital limitations  
Tissue Mobilization  Physiotouch Applied proximal to distal in areas with pathological skin in 
sections  
Arm Mobility  Passive Range of Motion Hold end position of joint for 3-10 seconds. (Dependent on skin 
and joint integrity) Repeat for each affected joint/digit 
Active Range of Motion 
Functional Activities (limited due to time) 
Home Range of Motion 
Exercises 
 Tailored active and passive ROM based on limitations in upper 
extremity mobility 
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Disease Duration, (mean, SD) 
Diffuse cutaneous SSc  
Interstitial Lung Disease (%, n) 
Gastrointestinal Involvement (%, n) 
Raynaud's Phenomenon (%, n) 
Use of Immunosuppressive Agents (%, n) 
3.1 (2.3) years 
100% 
42.9%  
81.0% 
90.5% (19) 
48% (10) Mycophenolate Mofetil (MMF) 
23.8% (5) Methotrexate 
9.5% (2) MMF and Methotrexate 
19.1% (4) Investigational agents 
4.8% (1) Abatacept*   
19.1% (4) None  
* n = 20  
Table 3. Least Square Means (SE) of Change over Time from Linear Mixed Models 
 Baseline Mid-treatment 
(4 weeks) 
Post-treatment 
(8 weeks) 
P value 
 Primary Outcome    
QuickDASH† 49.3 (4.6) 42.7 (4.8) 35.2 (4.8) 0.0012 
 Secondary Outcomes    
PROMIS Physical Function‡  38.0 (1.3) 38.5 (1.4) 41.1 (1.4) 0.004 
Left Total Active Motion§ 736.5 (41.0) 797.3 (41.3) 778.0 (41.3) 0.013 
Right Total Active Motion 745.2 (43.1) 775.5 (43.4) 758.0 (43.4) 0.49 
Left 9 Hole Peg Test (sec) 25.4 (1.6) 21.5 (1.6) 22.9 (1.6) 0.03 
Right 9 Hole Peg Test (sec) 23.6 (1.6) 21.9 (1.6) 21.8 (1.6) 0.15 
Handgrip Strength¶ 45.8 (4.1) 45.4 (4.1) 43.3 (4.1) 0.06 
† A higher score denotes worse function. 
‡ A higher score denotes better function.  
§ total active motion is 1175 degrees of movement total-260 degrees for each finger and 135 for 
thumb; right hand total active motion n = 20. 
¶ Handgrip strength is the maximum value from either hand. 
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Assessed for Eligibility (n = 48) 
-approached during clinic visits (n = 31) 
-registry (n = 17) 
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Enrolled in Treatment (n=21) 
Intent to treat (n = 21) 
Completers (n= 19) 
 
Received allocated intervention 
(all 8 visits) (n= 19) 
Received 3 sessions (n = 1) 
Received 2 sessions (n = 1) 
 
   Discontinued intervention (n=2) 
-travel constraints (n=2)  
> 200 miles Round trip from Center 
 
 
 
Consented (n=24) 
A
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w
-
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A
n
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is
 
-not eligible (overlap of 
scleroderma and RA)  
(n = 1) 
-Not available due to work 
constraints (n = 1) 
-Lost to follow-up (n = 1) 
 
-Declined to 
participate (n = 24) 
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FIGURE LEGENDS. 
Figure 1. Participant Flow Diagram 
Figure 2. Participant Photos Depicting Change in Upper Extremity Mobility from Baseline to 8 
Weeks 
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Appendix. Excerpt from the Treatment Protocol.  
This manual was developed by Susan Murphy, Mary Barber and Carole Dodge with input from 
the entire study team 
DESCRIPTION OF TREATMENT 
 The occupational therapy practitioner will work individually with patients following the 
general pattern below.   Treatment will be tailored based on specific characteristics of the participant (severity of 
contractures and inflammation) and will be progressed as participants improve.   Each session will end with a description and reminder to complete the home exercise 
program.  At the beginning of each session, the interventionist will discuss the following with the 
participant:  
o Any symptoms or functional issues that have been problematic during the last 
week as these may be important to focus on during treatment. 
o The partiĐipaŶt’s aďilitǇ to eŶgage iŶ the hoŵe eǆerĐise prograŵ aŶd ǁill go oǀer 
any questions or concerns.  
o How often the participant completed the home exercises in the last week and 
will emphasize the importance of completing the exercises if adherence is low.  
 
Table 1. Overview of treatment (Additional explanation for focus areas follow) 
Focus Area Treatment Instructions Time 
Preparation 
for 
Treatment 
Thermal Modalities  Hot packs  Paraffin  
 Focus thermal treatments on 
areas with limitations  Hot packs (elbows/forearms)   Paraffin (hands) 
15 minutes 
Tissue 
Mobilization 
Physiotouch (also 
called Lymphatouch)* 
 Begin about elbow, move 
proximally – 4 pulses per head 
10-13 minutes 
per extremity 
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 Apply proximal 
to distal in 
areas with 
pathological 
skin in sections  Use largest 
head that will 
achieve good 
suction 
 
placement/slightly overlap head 
placements 
Head size – 60/50/35 mm 
depending on location 
Pressure setting- 250 mmHg 
Vibration- 60 Hz 
Simple pulse – 2 sec/50%  End with hand/digits with same 
settings as above 
 
Arm 
Mobility 
Range of 
Motion 
Passive Range of 
Motion 
 
 
 
 
 
Active Range of 
Motion 
 
 
Functional Activities 
PROM Hold end position of joint for 
3-10 seconds; 3-5 reps (Dependent 
on skin and joint integrity) see 
Appendix Repeat for each affected joint/digit 
AROM – 10 reps - see Appendix  
 
 
Functional Activities utilizing 
available ROM, grip/pinch 
 
10 minutes per 
extremity 
 
 
 
 
3-5 minutes per 
extremity (or 
remaining time 
in session) 
 
 
Home 
Program  
Tailored active and 
passive ROM based on 
limitations in upper 
extremity mobility 
*Adaptions may be needed if skin 
ulcers are present by teaching 
alternative methods for 
holding/stretching joints, or if 
patient experiences lasting increase 
of musculoskeletal pain by 
decreasing repetitions. 
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Preparation for Treatment  
Thermal modalities are recommended to prepare the upper extremity for movement.  
The thermal modalities used in this treatment are hot packs and paraffin.  
Hot packs 
Materials needed  2 medium-size hot packs  2 bath-size towels (should be 8 layers between hot pack and skin) 
Instructions   Hot packs to elbows and forearms can be applied immediately prior to the treatment 
session (such as while participant is in reception area) or concurrently with the paraffin 
wax dips to the hands.   Hot packs should be encased in hot pack cover and towels and applied to elbows and 
forearms.  
Important Points   NEVER put a hot pack over the paraffin as this may cause harm to the participant.  ALWAYS listen to the participant and adjust heat and application of hot packs according 
to participant tolerance. For instance, more towels can be added around heat packs to 
reduce the heat.  
Paraffin Wax 
Paraffin is a thermal modality which is used to reduce pain, reduce joint stiffness, improve 
blood flow, moisturize skin and improve scar elasticity. 
 Materials need   Paraffin unit with adjustable heat control 
 Paraffin wax (approximately 6 lbs. of prepared wax)  
 Candy or meat thermometer 
 Exam gloves – latex or non-latex (if needed) 
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 Medical tape (if needed) 
 Additional small bottle of mineral oil (if needed to lower temperature) 
Instructions  Heat wax to at least 120 degrees Fahrenheit but no more than 130 degrees - test with a 
thermometer.  Have participant prepare for treatment by removing any rings, washing hands with 
soapy water, and rinsing and drying hands.  Dip one hand with a straight wrist and fingers as relaxed and separated as possible into 
the wax (being careful not to crack the wax).  Immediately pull hand out of wax after dipping.   After no more wax drips off of the hand, dip again for a recommended 8 – 12 times in 
the same manner (See Important Points section below).   Insert hand into a plastic bag and then wrap in a towel or mitt to retain heat.   Repeat process of dipping with the other hand. 
Important Points   Listen to the participant regarding their tolerance. Ask participant after a few dips how it 
feels, and if the temperature is getting too warm, do not continue to dip. 
 If patient has an ulcer on one of their digits or thumb, paraffin can still be used if the 
area is adequately protected. For instance, an exam glove can be used over the hand 
with tape applied around the top of glove to keep wax from getting in the wound.  
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